Title |
Procalcitonin for Diagnostics and Treatment Decisions in Pediatric Lower Respiratory Tract Infections
|
---|---|
Published in |
Frontiers in Pediatrics, August 2017
|
DOI | 10.3389/fped.2017.00183 |
Pubmed ID | |
Authors |
Philipp Baumann, Gurli Baer, Jessica Bonhoeffer, Aline Fuchs, Verena Gotta, Ulrich Heininger, Nicole Ritz, Gabor Szinnai, Jan Bonhoeffer |
Abstract |
Mortality and morbidity remain high in pediatric lower respiratory tract infections (LRTIs) despite progress in research and implementation of global diagnostic and treatment strategies in the last decade. Still, 120 million annual episodes of pneumonia affect children younger than 5 years each year leading to 1.3 million fatalities with the major burden of disease carried by low- and middle-income countries (95%). The definition of pneumonia is still challenging. Traditional diagnostic measures (i.e., chest radiographs, C-reactive protein) are unable to distinguish viral and from bacterial etiology. As a result, common antibiotic overuse contributes to growing antibiotic resistance. We present an overview of current evidence from observational and randomized controlled trials on a procalcitonin (PCT)-based diagnosis of pediatric LRTIs and discuss the need for an adequate PCT threshold for antibiotic treatment decision-making. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 61 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 9 | 15% |
Researcher | 9 | 15% |
Student > Bachelor | 6 | 10% |
Student > Postgraduate | 5 | 8% |
Student > Doctoral Student | 4 | 7% |
Other | 12 | 20% |
Unknown | 16 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 32 | 52% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Business, Management and Accounting | 2 | 3% |
Immunology and Microbiology | 2 | 3% |
Agricultural and Biological Sciences | 2 | 3% |
Other | 3 | 5% |
Unknown | 18 | 30% |